10-Q: Anixa Biosciences Q3 2026: Development Continues Amidst Net Losses

Anixa Biosciences reports continued investment in its cancer vaccine and CAR-T therapy programs, with no revenue generated and ongoing net losses for the third quarter of fiscal year 2026.

Summary

• Anixa Biosciences, Inc. filed its Form 10-Q for the quarterly period ended July 31, 2026.
• The company reported no revenue for the three and nine months ended July 31, 2026, consistent with prior periods.
• Research and development expenses for the three months ended July 31, 2026, were $1.33 million, an increase from $1.06 million in the same period of 2025.
• General and administrative expenses for the three months ended July 31, 2026, were $1.41 million, a slight increase from $1.38 million in the same period of 2025.
• The net loss for the three months ended July 31, 2026, was $2.63 million, compared to a net loss of $2.28 million for the same period in 2025.
• For the nine months ended July 31, 2026, the net loss was $7.75 million, a decrease from $8.31 million for the same period in 2025.
• The company had $13.9 million in cash, cash equivalents, and short-term investments as of July 31, 2026.
• Anixa Biosciences believes its current liquidity is sufficient for at least the next twelve months.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the continued lack of revenue and significant net losses, despite ongoing development efforts.

Positives

• Continued progress in clinical trials for lira-cel (CAR-T therapy) for ovarian cancer, with some patients showing anecdotal signs of efficacy and extended survival.
• Phase 1 trial for the breast cancer vaccine completed enrollment in June 2025 and all patient visits in October 2025, with final data presented in December 2025 showing primary endpoints met, immune responses observed in 74% of subjects, and the vaccine being safe and well-tolerated.
• Preparation to initiate a Phase 2 clinical trial for the breast cancer vaccine in the neo-adjuvant setting.
• The company has approximately $13.9 million in cash, cash equivalents, and short-term investments as of July 31, 2026, which management believes is sufficient for at least the next twelve months.
• Raised approximately $4.8 million net of expenses through an at-the-market equity offering during the nine months ended July 31, 2026.
• The NCI's PREVENT program is supporting the pre-clinical development, manufacturing, and IND enabling studies for the ovarian cancer vaccine at no material financial expenditure by the company.
• Entered into a Joint Development and Option Agreement with Cleveland Clinic to develop additional cancer vaccines.

Negatives

• No revenue was generated during the three and nine months ended July 31, 2026.
• Net loss for the three months ended July 31, 2026, was $2.63 million, an increase from $2.28 million in the prior year period.
• Net loss for the nine months ended July 31, 2026, was $7.75 million, although this is a decrease from $8.31 million in the prior year period.
• Research and development expenses increased by approximately $271,000 to $1.33 million for the three months ended July 31, 2026, compared to the prior year period.
• The company's cash, cash equivalents, and short-term investments decreased by approximately $1.31 million during the nine months ended July 31, 2026.
• The company does not expect to generate revenue from its current therapeutics or vaccine programs in the near term.

Risks

• The company's ability to continue as a going concern is dependent on its ability to secure additional funding and achieve profitability.
• The development of therapeutics and vaccines is a lengthy, expensive, and uncertain process with no guarantee of success.
• The company relies on third-party collaborators and licensors, and any disruption in these relationships could impact development timelines.
• The company's CAR-T therapy and vaccine programs are still in early-stage clinical trials, and results are preliminary and may not be indicative of future outcomes.
• The company may face challenges in obtaining regulatory approval for its products.
• The company's stock price is subject to volatility due to the inherent risks associated with biotechnology companies.

Future Outlook

The company believes its current cash, cash equivalents, and short-term investments are sufficient to fund its activities for at least the next twelve months. Management expects the development of its therapeutics and vaccines to be the primary focus, with no expectation of generating revenue from these programs in the near term. The company may also make investments in and form new companies to develop additional emerging technologies. The company has an at-the-market equity program under which it may sell approximately $95 million of common stock.

Management Comments

• "We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies."
• "Based on currently available information as of September 9, 2026, we believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our activities for at least the next twelve months."
• "We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as therapeutics or vaccines."
• "While the results are preliminary and in a small number of subjects, multiple patients have exhibited anecdotal signs of efficacy, including possible signs of T cell infiltration, tumor necrosis and encouraging survival observations."

Industry Context

StockSavvy.ai notes that Anixa Biosciences operates in the highly competitive and capital-intensive biotechnology sector, focusing on oncology. The company's strategy of developing novel cancer vaccines and CAR-T therapies aligns with significant industry trends, but the prolonged development cycles and high failure rates are characteristic of the sector. The lack of revenue and reliance on external funding and partnerships are common for companies at this stage of development.

Comparison to Industry Standards

• Many early-stage biotechnology companies, like Anixa, operate with significant R&D expenses and net losses for extended periods, relying on equity financing and strategic partnerships to fund operations.
• The development timelines for CAR-T therapies and cancer vaccines are typically long, often spanning 5-10 years from discovery to market approval, with Phase 1 trials focusing on safety and tolerability, similar to Anixa's current stage.
• Companies in the oncology space often collaborate with academic institutions (like Wistar Institute and Cleveland Clinic) and research hospitals (like Moffitt Cancer Center) to leverage expertise and resources, a model Anixa employs.
• The success rates for drugs entering Phase 1 clinical trials are generally low, with only a fraction progressing to market approval. Anixa's preliminary positive safety and anecdotal efficacy data in its trials are encouraging but must be viewed within this context.

Legal Proceedings

• Other than lawsuits related to the enforcement of patent rights, the company is not a party to any material pending legal proceedings.

Stakeholder Impact

• Shareholders: Continued investment in R&D without current revenue may lead to further dilution if capital is raised, but also holds potential for future returns if development is successful.
• Employees: Continued employment is dependent on the company's ability to secure funding and achieve milestones.
• Collaborators (Wistar Institute, Cleveland Clinic, Moffitt Cancer Center): Continued collaboration is essential for ongoing research and development activities.

Next Steps

• Prepare to initiate a Phase 2 clinical trial for the breast cancer vaccine in the neo-adjuvant setting.
• Continue development of lira-cel (CAR-T therapy) for ovarian cancer.
• Continue vaccine discovery programs for lung, colon, and prostate cancers.
• Potentially utilize the at-the-market equity program to raise additional capital.

Key Dates

Recommendation

Anixa Biosciences is a speculative investment in the biotechnology sector. While there is promising early-stage clinical data for its cancer vaccine and CAR-T therapy programs, the company continues to incur significant losses with no current revenue. The company's ability to execute its development plans and secure future funding are critical. Investors should be aware of the high risks associated with early-stage drug development. A 'hold' recommendation reflects the potential upside balanced against the substantial risks and ongoing cash burn.

Keywords

biotechnology, oncology, cancer vaccines, CAR-T therapy, clinical trials, ovarian cancer, breast cancer, drug development